The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a doubleblind manner into two groups: group 1 (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), troponin I, creatine kinase and brain natriuretic peptide plasma levels], ECG and echocardiogram were performed at baseline and daily up to discharge. All of the patients were followed as outpatients for 3 months to evaluate any recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters [group 1 (the statin group), n = 28 patients; gender, 18 male and ten female; and age, 29.5 + − 5.7 years; group 2 (placebo group), n = 27 patients; gender, 16 male/11 female; and age, 29.2 + − 4.8 years]. The statin group, when compared with the placebo group, had a significantly faster reduction in CRP values (5.0 + − 1.0 compared with 6.0 + − 2.0 days respectively; P = 0.022), ST segment normalization (3.5 + − 1.0 compared with 4.5 + − 1.0 days respectively; P = 0.001), pericardial effusion (4.5 + − 1.0 compared with 5.5 + − 1.0 days respectively; P = 0.001) and ESR (5.0 + − 1 compared with 6.0 + − 2 days respectively; P = 0.022). Our results show that the combination of statin and indomethacin treatment in patients with acute pericarditis is feasible, with a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5 + − 2.0 compared with 6.5 + − 2.0 days respectively; P = 0.069). However, these preliminary findings require further studies in a larger sample of patients.
A B S T R A C T
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INTRODUCTION
Acute pericarditis is a common and frequent disease to be considered in the differential diagnosis of chest pain. Most patients with acute pericarditis have either viral or idiopathic pericarditis. In many cases, acute pericarditis has a brief and benign course after empirical treatment with NSAIDs (non-steroidal anti-inflammatory drugs). A viral aetiology is often presumed, but evidence for this is not often sought due to the expense involved and the time required before the results of laboratory tests are available. The aims of treatment are to relieve symptoms, and most patients are hospitalized for complete diagnosis and observation of complications, particularly pericardial effusion and cardiac tamponade [1, 2] . Although as many as 90 % of isolated cases of acute pericarditis are idiopathic or viral, the list of other potential causes is extensive. The mainstay of therapy is NSAIDs, although colchicine has also shown promise in the treatment of recurrent pericarditis [3] . Indomethacin and other NSAIDs can inhibit the activity of COX (cyclo-oxygenase), a property which accounts for their shared therapeutic effects [4] . Previous studies have shown that it is possible to modulate CRP (C-reactive protein) levels with pharmacological intervention, including HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitor drugs such as statins [5] [6] [7] . The latter also reduce cardiovascular risk by diminishing arterial inflammation, as suggested by a reduction in serum CRP levels; this appears to be independent of a reduction in LDL-cholesterol (low-density lipoprotein cholesterol) levels [8, 9] . On the basis of these findings, a pilot study was carried out to evaluate the safety and feasibility of the combination of indomethacin and a statin, and whether this could prove to be more effective than indomethacin plus placebo in patients with a first episode of acute pericarditis. Our endpoints were: (i) feasibility and safety; and (ii) effects on clinical inflammatory markers, pericardial effusion and ST-segment evolution.
MATERIALS AND METHODS

Study subjects and enrolment
A total of 55 consecutive patients, hospitalized for a first episode of acute pericarditis at G.F. Ingrassia Hospital, Palermo, Italy, were studied prospectively between January 2005 and December 2006.
Inclusion criteria for patients included: age > 18 years, prodrome of fever, malaise and myalgia, retrosternal or left precordial chest pain and shortness of breath, rapid and regular heart rate, pericardial friction rub, elevated WCc (white cell count; > 10 × 10 9 cells/l), elevated ESR (erythrocyte sedimentation rate; > 35 mm/h), high values of serum CRP (> 0.5 mg/dl), plasma TNI (troponin I; > 1.0 pg/ml), serum CK [creatine kinase; > 80 IU (international units)/l] and its MB fraction concentration [1, 2, 10, 11] , classical ECG alterations (widespread upward concave ST-segment elevation and PR-segment depression) and echocardiographic evidence of a small pericardial effusion on admission (an echofree space, anterior plus posterior of < 10 mm during diastole) [12] . As this was a pilot study, only patients with small pericardial effusion were included. Acute pericarditis was diagnosed when at least four of the following criteria were present: pericarditic chest pain, pericardial friction rub, widespread ST-segment elevation on the ECG, echocardiographic evidence of a small pericardial effusion, elevated WCc, elevated ESR, high values of serum CRP, and increased values of TNI and CK and its MB fraction.
Exclusion criteria included: patients with infections, kidney failure, metastatic disease, those receiving medication and radiation therapy, history of recent heart attack (myocardial infarction), rheumatoid arthritis and lupus, tuberculosis and AIDS, recent chest trauma and patients receiving anti-inflammatory drugs before hospitalization, statin etc. Considering that most cases probably had a viral or idiopathic aetiology, with a possible brief and benign course after NSAIDs, we intentionally avoided performing an initial full diagnostic evaluation in all cases.
The present study was performed in accordance with the Declaration of Helsinki, and written informed consent was obtained from each patient before starting the study. The protocol was approved by the local Ethics Committee.
Study protocol and follow-up
After admission, the enrolled patients were randomized in a double-blinded manner into two groups: group 1 (statin group) received 150 mg of indomethacin plus 10 mg of rosuvastatin daily, whereas group 2 (placebo group) received 150 mg of indomethacin plus placebo daily. Both groups received the treatments (rosuvastatin plus indomethacin or placebo plus indomethacin) up to the normalization of inflammatory markers (CRP < 0.5 pg/ml, WCc < 7 × 10 9 cells/l and ESR < 20 mm/h) and for the whole of the following week. After baseline clinical and laboratory assessments, patients were evaluated daily with a complete physical examination, a careful symptom check, along with BP (blood pressure) and heart rate determinations; blood samples were drawn daily to determine WCc, ESR, CRP, TNI, CK/MB (Dade Behring Diagnostics), pro-NT-BNP plasma levels [pro-N-terminal BNP (brain natriuretic peptide); Roche], serum urea and creatinine. All laboratory measurements were performed in a core laboratory, and a validated assay for high-sensitive CRP was used (Dade Behring). A chest X-ray was performed on admission and at discharge, and ECGs and echocardiograms were performed daily up until discharge in order to monitor pericardial effusion. After discharge, the patients were followed-up as outpatients every week for the first month and every 2 weeks for the subsequent 2 months to evaluate the recurrence of pericarditis. Clinical evaluation, ECG, echocardiographic and laboratory assessments were performed at every follow-up by two physicians blinded to the group assignments to evaluate if recurrence of pericarditis had occurred. No other anti-inflammatory drug was added or used during the study period. The side effects of indomethacin were recorded, and omeprazole (20 mg/day) was administered for gastroprotection.
Statistical analysis
Continuous data are means + − S.D. and were compared using the unpaired Student's t test and ANOVA for repeated measures with Bonferroni correction for intragroup comparison. Categorical variables are expressed as proportions or percentages and were compared using χ 2 analysis. A P value of < 0.05 was considered statistically significant.
RESULTS
All of the 55 enrolled patients [mean age, 29.3 + − 5.2 years (range, 20-38 years); 34 men and 21 women] had acuteonset pericardial chest pain and ST-segment elevation with a typical ECG evolution at entry. Pericardial friction rub was present in 45 patients, and small pericardial effusion was present in 47 patients. Treatment was effective in all of the 55 cases and no patient displayed initial treatment failure. The treatment was well-tolerated without serious drug side effects. Only one minor side effect, including dyspepsia, abdominal pain and gastritis (from the statin group), was recorded. After a mean follow-up of 3 months, no recurrence of pericarditis or any rebound effect after discontinuing the statin therapy were observed. The two groups were similar in clinical characteristics, age, sex and laboratory parameters ( Table 1 ). As shown in Table 2 , the statin group had a significantly faster reduction/normalization in CRP values (P = 0.022), ST segment normalization (P = 0.001), pericardial effusion (P = 0.001) and ESR (P = 0.022), whereas WCc and hospitalization time were not significant, but did have a trend towards significance (P = 0.069). These results were calculated when patients were completely free of symptoms and, at the same time period, ESR and WCc were within the normal range (< 20 mm/h and < 7 × 10 9 cells/l respectively). This time point was also chosen to analyse CRP values. TNI and CK/MB in patients with increased levels at entry did not show any differences in normalization time (Table 2) and plasma levels during the study period (results not shown). The absence of any effects of statin + indomethacin treatment on TNI and CK/MB was probably due to the kinetics of myocardial enzymes, which usually depend on baseline values and represents myocardial damage already present at entry. Pro-NT-BNP values were within normal range (< 125 pg/ml) at admission and during the study period (results not shown). Table 3 shows the daily variations in plasma inflammatory markers (WCc, ERS and CRP) during hospitalization. The statin group had earlier changes in CRP, WCc and ESR compared with the placebo group. These results are 
DISCUSSION
The present study indicates the safety of a combined statin + indomethacin therapy. Moreover, this combination resulted in an earlier normalization of clinical and laboratory inflammatory markers in patients with a first episode of acute pericarditis. To date, this is the first time that a combination of an NSAID and a statin has been used in the setting of such patients. This treatment took into consideration the results of previous studies in which the important anti-inflammatory effects of statins were discussed [13] [14] [15] . Statins can interfere with the pro-inflammatory pathway of adhesion and migration at the level of protein expression and function. For example, statins diminish the expression of the integrin dimer CD11b [Mac-1, the cognate ligand of ICAM-1 (intercellular adhesion molecule-1) on the endothelium and other cells] on monocytes, and they also inhibit the adhesion of leucocytes to endothelial cells [16] [17] [18] . Statins can selectively inhibit leucocyte adhesion by direct interaction with LFA-1 (leucocyte-function antigen-1), thereby providing definitive evidence for functions that are independent of their lipid-lowering effects [19] . By binding to a new allosteric site within this β2 integrin, rather than targeting HMG-CoA reductase, statins block the adhesion of lymphocytes to the endothelium to such a degree as to suppress the inflammatory response in peritonitis in mice. [19] . Statins are also reported to ameliorate inflammatory diseases in murine autoimmune models, by inhibiting Th1 (T-helper 1) responses [20] , and to influence cell activation through the inhibition of NF-κB (nuclear factor κB) [21, 22] and diminished T-cell proliferation, probably via the direct engagement of the T-cell receptor [23, 24] . The type of immune response supported may also depend on the ability of statins to induce the release of Th2-promoting cytokines [e.g. IL (interleukin)-4, IL-5, IL-10 or TGF-β (transforming growth factor-β] and diminish the secretion of Th1 cytokines (e.g. IL-2, IL-12 or interferon) [25] . Statins may also repress the activation of T-lymphocytes by inhibiting MHC class II antigen expression. [26] . Notably, HMGCoA reductase inhibitors also regulate the expression and function of these mediators. In addition, statins prevented AF (atrial fibrillation) in an experimental model of pericarditis with elevated CRP, and prevented the promotion of atrial electrophysiological and structural changes resulting from inflammation [27] . Similarly, a clinical study [28] has shown that the use of statins in patients with lone AF was associated with a decrease in the recurrence of AF after successful cardioversion. These results show that statins can mediate modest, but clinically apparent, anti-inflammatory effects by modifying vascular risk factors in the context of highgrade autoimmune inflammation [29] . Indomethacin is a widely used NSAID, and it is generally known to exhibit multiple biological functions by inhibiting COXs. Indomethacin inhibits the activity of COX by decreasing the formation of the precursors of PGs (prostaglandins) and thromboxanes from arachidonic acid or by activating PPARs (peroxisomeproliferator-activated receptors) [30] ; however, previous studies have revealed that a number of the actions of indomethacin are independent of COXs [31] . In addition, it has been shown that the novel PGD 2 receptor CRTH2 (chemoattractant receptor-homologous molecule), which is expressed on Th2 cells, is another functional target of indomethacin [32, 33] . Furthermore, indomethacin was able to reduce virus infection at a post-binding step early in the infection cycle, thereby inhibiting virus protein synthesis, but it did not appear to affect viral RNA synthesis [34] .
We hypothesized that the combination of both drugs, which display different actions in the inflammatory process, could result in an enhancement of their antiinflammatory effects and could also explain the observed effects on plasma CRP levels from day 1 of treatment. We studied patients with acute pericarditis because these patients are young and with no other diseases that could interfere with the inflammatory state determined by pericarditis. The randomized patient sample comprised patients exclusively at low risk, because this was the first time that this combination had been used. Indeed, the primary end point was safety and feasibility. The effects observed on clinical and laboratory inflammatory markers were of great interest, but the low number of patients and short observation period were insufficient to permit definitive conclusions. We believe that the favourable trend in reducing hospitalization time (although not significant), and the significant earlier normalization in ST-segment elevation and pericardial effusion were obtained due to a more rapid cessation in the inflammatory process. Nevertheless, our present results are insufficient to suggest additive or synergistic effects of the statin + indomethacin combination and should, therefore, be considered as a preliminary observation and to be interpreted with caution. Further investigation, however, is warranted.
